# nature portfolio

Corresponding author(s): Caili Huang

Last updated by author(s): November 10, 2024

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

#### **Statistics**

Fora	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	ifrmed
	X	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	×	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
×		A description of all covariates tested
	x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	×	For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	1	Our web collection on statistics for biologists contains articles on many of the points above.

## Software and code

Policy information about availability of computer code

Data collection	Microsoft Excel (Version 16.77.1) was used for interfacial tension, FTIR data, Zeta potential, rheological parameter (storage modulus, loss modulus and apparent viscosity), biochemical detection (CAT and SOD activity, MDA, IL-1β, IL-6, and TNF-α level) data collection, Gaussian data, UV-visible absorption data for β-carotene, UV shielding data. FV31S-SW Viewer software was used for fluorescence image acquisition. Image-Pro Plus 6.0 software was used for histological image acquisition.
Data analysis	Image J (Version 1.53k) was used to measure the wound area, epidermal thickness and keratin percentage of mouse skin. Avizo software (Visualization Sciences Group) was used to measure the Gaussian curvature, K, of bridged emulsion gels. All statistical analyses were performed on GraphPad Prism 10.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data supporting the findings of this study are available within the article and its supplementary files. Source data are provided with this paper. All data underlying this study are available from the corresponding author upon request.

#### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation),</u> and sexual orientation and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.
Reporting on race, ethnicity, or other socially relevant groupings	Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.)
	Please provide details about how you controlled for confounding variables in your analyses.
Population characteristics	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
Ethics oversight	Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to predetermine the sample sizes. Sample sizes (five mice per group) in our study were comparable to similar studies in the field, e.g. Nat. Protoc. 2024, 19, 184; Cell Rep. Phys. Sci. 2023, 4, 101308.
Data exclusions	No data were excluded from the analyses.
Replication	All experiments were repeated three times and found to be reproducible.
Randomization	Mice were randomly allocated into different groups.
Blinding	Blinding and randomization were applied to all experiments.

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

#### Materials & experimental systems

Methods
---------

n/a	Involved in the study	n/a	Involved in the study
	X Antibodies	×	ChIP-seq
	Eukaryotic cell lines	×	Flow cytometry
×	Palaeontology and archaeology	×	MRI-based neuroimaging
	<ul><li>Animals and other organisms</li></ul>		
×	Clinical data		
×	Dual use research of concern		
×	Plants		

### Antibodies

Antibodies used	IL-1β (BioLegend; 432615) IL-6 (BioLegend; 431315) TNF-α (BioLegend; 430915)
Validation	<ul> <li>IL-1β (BioLegend; 432615) validated by the manufacturer (https://www.biolegend.com/en-gb/products/mouse-il-1beta-elisa-max-deluxe-3113).</li> <li>IL-6 (BioLegend; 431315) validated by the manufacturer (https://www.biolegend.com/en-gb/products/mouse-il-6-elisa-max-deluxe-2251).</li> <li>TNF-α (BioLegend; 430915) validated by the manufacturer (https://www.biolegend.com/en-gb/products/mouse-tnf-alpha-elisa-max-deluxe-2243).</li> </ul>

### Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>		
Cell line source(s)	The human keratinocyte cell line HaCaT (Haixing Biosciences; TCH-C388); of male origin	
Authentication	Quality testing for HaCaT used in our study is provided on the website of Haixing Biosciences (https://www.cas9x.com/bdxb/105217.html). Specifically, short tandem repeat (STR) profiling is used to identify cell lines.	
Mycoplasma contamination	The used cell line tested negative for mycoplasma contamination.	
Commonly misidentified lines (See <u>ICLAC</u> register)	No commonly misidentified cell lines were used in the study.	

## Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals	Eight-week-old BALB/c female mice (18–20 g) were purchased from the Hubei Provincial Center for Disease Control and Prevention. All mice were housed in individually ventilated cages and maintained on a 12 h light/dark cycle at room temperature (25±1°C) with constant humidity (55±10%). All mice were supplied with food and water ad libitum.
Wild animals	This study did not involve wild animals.
Reporting on sex	Female mice were used in this study.
Field-collected samples	This study did not involve samples collected from the field.
Ethics oversight	All animal procedures were performed in accordance with Huazhong University of Science and Technology animal use rules and the
	requisite approvals of animal use committees (Approval No. [2023] IACUC Number: 4135).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Plants

Seed stocks	Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.
Novel plant genotypes	Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor
Authentication	was applied. Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-taraet aene editina) were examined.